Drug intelligence / Profile preview

cyclophosphamide + bismuth subgallate + prednisone + etoposide + procarbazine

Development stage
Unknown
Lead developer
Takeda
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral, Intravenous, Topical
01

Overview

This combination involves **cyclophosphamide**, a nitrogen mustard alkylating agent used in chemotherapy; **bismuth subgallate**, a compound with hemostatic and wound healing properties; **prednisone**, a corticosteroid; **etoposide**, a topoisomerase inhibitor; and **procarbazine**, an alkylating agent. Cyclophosphamide is used in treating cancers and autoimmune diseases, while prednisone is used for its anti-inflammatory effects. Etoposide and procarbazine are primarily used in cancer treatment. Bismuth subgallate is not commonly used in cancer treatment but has been explored for surgical applications due to its hemostatic properties.

02

Targets

DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on cyclophosphamide + bismuth subgallate + prednisone + etoposide + procarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + bismuth subgallate + prednisone + etoposide + procarbazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call